Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 31 to 45 of 46 results for back pain sciatica

  1. Cost saving guidance

    anticipated bed day savings. Capacity savings: £11,600 Guideline on low back pain and sciatica in over 16s:...

  2. Chronic pain (primary and secondary) in over 16s: assessment of all chronic pain and management of chronic primary pain (NG193)

    This guideline covers assessing all chronic pain (chronic primary pain, chronic secondary pain, or both) and managing chronic primary pain in people aged 16 years and over. Chronic primary pain is pain with no clear underlying cause, or pain (or its impact) that is out of proportion to any observable injury or disease.

  3. What is the clinical and cost effectiveness of opioids for the management of acute sciatica?

    clinical and cost effectiveness of opioids for the management of acute sciatica? Any explanatory notes(if applicable) Why the committee

  4. What is the clinical and cost effectiveness of antidepressants for the management of sciatica?

    clinical and cost effectiveness of antidepressants for the management of sciatica? Any explanatory notes(if applicable) Why the...

  5. Epidurals:- What is the clinical and cost effectiveness of image-guided compared with non-image-guided epidural injections for people with acute sciatica?

    compared with non-image-guided epidural injections for people with acute sciatica? Any explanatory notes(if applicable) Why this is...

  6. What is the clinical and cost effectiveness of opioids for the management of acute sciatica?

    of acute sciatica? Any explanatory notes(if applicable) Source guidance details Comes from guidance Low back...

  7. Pharmacological therapies:- What is the clinical and cost effectiveness of benzodiazepines for the acute management of low back pain?

    cost effectiveness of benzodiazepines for the acute management of low back pain? Any explanatory notes(if applicable) Why...

  8. Radiofrequency denervation:- What is the clinical and cost effectiveness of radiofrequency denervation for chronic low back pain in the long term?

    clinical and cost effectiveness of radiofrequency denervation for chronic low back pain in the long term? Any explanatory...

  9. Suspected neurological conditions: recognition and referral (NG127)

    This guideline covers the initial assessment of symptoms and signs that might indicate a neurological condition. It helps non-specialist healthcare professionals to identify people who should be offered referral for specialist investigation.

  10. Community pharmacies: promoting health and wellbeing (NG102)

    This guideline covers how community pharmacies can help maintain and improve people’s physical and mental health and wellbeing, including people with a long-term condition. It aims to encourage more people to use community pharmacies by integrating them within existing health and care pathways and ensuring they offer standard services and a consistent approach. It requires a collaborative approach from individual pharmacies and their representatives, local authorities and other commissioners.

  11. Accuro for guiding epidural or spinal anaesthesia (MIB245)

    NICE has developed a medtech innovation briefing (MIB) on Accuro for guiding epidural or spinal anaesthesia .

  12. Percutaneous coblation of the intervertebral disc for low back pain and sciatica (IPG543)

    We have moved interventional procedures guidance 543 to become HealthTech guidance 397. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

  13. Percutaneous electrothermal treatment of the intervertebral disc annulus for low back pain and sciatica (IPG544)

    We have moved interventional procedures guidance 544 to become HealthTech guidance 398. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

  14. NICE has made six times more lung cancer treatment recomendations over the past ten years than in the previous decade

    We have also recommended osimertinib for routine use on the NHS today.